TAC-话题@MedSci

#TAC#

115篇内容 | 2662人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2033751, encodeId=35c72033e5147, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=A&R：血浆中的CRTAC1蛋白与骨关节炎相关并预测将来是否需要关节置换：冰岛的大规模蛋白质组学扫描, objectType=article, longId=221537, objectId=2b3822153e32, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b3822153e32, replyNumber=0, likeNumber=115, createdTime=2022-07-22, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b3822153e32, moduleTitle=A&R：血浆中的CRTAC1蛋白与骨关节炎相关并预测将来是否需要关节置换：冰岛的大规模蛋白质组学扫描, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b3822153e32)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033755, encodeId=19142033e559c, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=2022年1月10日简报：天津再新增20例奥密克戎感染；塞浦路斯研究人员称发现“德尔塔+奥密克戎”混合毒株Deltacron；南非仅2个月就渡过疫情高峰, objectType=article, longId=293684, objectId=1ab429368422, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ab429368422, replyNumber=0, likeNumber=110, createdTime=2022-11-21, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ab429368422, moduleTitle=2022年1月10日简报：天津再新增20例奥密克戎感染；塞浦路斯研究人员称发现“德尔塔+奥密克戎”混合毒株Deltacron；南非仅2个月就渡过疫情高峰, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ab429368422)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033746, encodeId=2b332033e46e9, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=Front Oncol：TACE联合索拉非尼或阿帕替尼治疗伴有门脉癌栓（PVTT）的肝细胞癌（HCC）患者的疗效, objectType=article, longId=219192, objectId=ab6d21919256, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab6d21919256, replyNumber=0, likeNumber=69, createdTime=2022-09-20, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab6d21919256, moduleTitle=Front Oncol：TACE联合索拉非尼或阿帕替尼治疗伴有门脉癌栓（PVTT）的肝细胞癌（HCC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab6d21919256)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033760, encodeId=fad72033e603e, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=Front Immunol：强直性脊柱炎患者外周血单个核细胞的整合单细胞RNA-SEQ和ATAC-SEQ分析, objectType=article, longId=299220, objectId=7c8429922054, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c8429922054, replyNumber=0, likeNumber=74, createdTime=2022-04-02, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c8429922054, moduleTitle=Front Immunol：强直性脊柱炎患者外周血单个核细胞的整合单细胞RNA-SEQ和ATAC-SEQ分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c8429922054)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033747, encodeId=3aab2033e478a, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=Front Oncol：肝切除术(HR)对比TACE治疗中期肝细胞癌(IM-HCC)的疗效, objectType=article, longId=219491, objectId=16ac219491e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16ac219491e4, replyNumber=0, likeNumber=72, createdTime=2022-04-12, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16ac219491e4, moduleTitle=Front Oncol：肝切除术(HR)对比TACE治疗中期肝细胞癌(IM-HCC)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16ac219491e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033770, encodeId=1a682033e709c, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=J AM COLL RADIOL：肝癌TACE术后该选择何种药物进行疼痛控制？, objectType=article, longId=731865, objectId=d093e3186597, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d093e3186597, replyNumber=0, likeNumber=121, createdTime=2023-01-06, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d093e3186597, moduleTitle=J AM COLL RADIOL：肝癌TACE术后该选择何种药物进行疼痛控制？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d093e3186597)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033764, encodeId=12242033e640c, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=Contact Dermatitis：新冠肺炎大流行期间实习护生手部湿疹的特点, objectType=article, longId=299231, objectId=a95a29923179, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a95a29923179, replyNumber=0, likeNumber=79, createdTime=2022-08-23, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a95a29923179, moduleTitle=Contact Dermatitis：新冠肺炎大流行期间实习护生手部湿疹的特点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a95a29923179)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033749, encodeId=eb962033e4952, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=治疗C3肾小球肾炎，诺华的 iptacopan 在中期研究中达到临床终点, objectType=article, longId=220407, objectId=751922040e38, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=751922040e38, replyNumber=0, likeNumber=71, createdTime=2022-10-26, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=751922040e38, moduleTitle=治疗C3肾小球肾炎，诺华的 iptacopan 在中期研究中达到临床终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=751922040e38)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033753, encodeId=d7522033e5317, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=Front Oncol：立体定向放疗（SBRT）联合免疫治疗（SBRT-IO）对比TACE治疗局部进展期肝细胞癌患者的疗效, objectType=article, longId=264987, objectId=306f26498e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=306f26498e26, replyNumber=0, likeNumber=78, createdTime=2021-12-27, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=306f26498e26, moduleTitle=Front Oncol：立体定向放疗（SBRT）联合免疫治疗（SBRT-IO）对比TACE治疗局部进展期肝细胞癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=306f26498e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033745, encodeId=57f22033e45a2, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=Aspaveli (pegcetacoplan) 治疗阵发性夜间血红蛋白尿症 (PNH)，已获得欧盟CHMP积极意见, objectType=article, longId=218729, objectId=4cd6218e291b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cd6218e291b, replyNumber=0, likeNumber=69, createdTime=2021-11-02, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cd6218e291b, moduleTitle=Aspaveli (pegcetacoplan) 治疗阵发性夜间血红蛋白尿症 (PNH)，已获得欧盟CHMP积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cd6218e291b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033750, encodeId=b1652033e50af, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=使用TACE联合放疗治疗原发性肝癌合并门静脉癌栓对患者生存情况的影响分析, objectType=article, longId=220980, objectId=a59a2209806a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a59a2209806a, replyNumber=0, likeNumber=63, createdTime=2022-03-06, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a59a2209806a, moduleTitle=使用TACE联合放疗治疗原发性肝癌合并门静脉癌栓对患者生存情况的影响分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a59a2209806a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033738, encodeId=e2422033e3817, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=Hepatology International：仑伐替尼+TACE对比TACE在不可切除肝癌中的疗效：一项回顾性对照研究, objectType=article, longId=211110, objectId=36e621111049, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36e621111049, replyNumber=0, likeNumber=63, createdTime=2021-07-13, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36e621111049, moduleTitle=Hepatology International：仑伐替尼+TACE对比TACE在不可切除肝癌中的疗效：一项回顾性对照研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36e621111049)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033761, encodeId=923e2033e6123, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=Liver Cancer：Lenvatinib(仑伐替尼)初始治疗出现应答是仑伐替尼（LEN)+经动脉化疗栓塞(LEN-TACE)序贯治疗的预后指标, objectType=article, longId=299284, objectId=0f55299284f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f55299284f7, replyNumber=0, likeNumber=73, createdTime=2022-03-31, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f55299284f7, moduleTitle=Liver Cancer：Lenvatinib(仑伐替尼)初始治疗出现应答是仑伐替尼（LEN)+经动脉化疗栓塞(LEN-TACE)序贯治疗的预后指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f55299284f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033743, encodeId=83282033e43a5, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=新药研发利器：PROTAC技术（全面解读）, objectType=article, longId=222072, objectId=16342220e2ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16342220e2ea, replyNumber=0, likeNumber=59, createdTime=2022-03-22, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16342220e2ea, moduleTitle=新药研发利器：PROTAC技术（全面解读）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16342220e2ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033737, encodeId=38f12033e3718, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=RSC Chem Biol：PROTAC的时代来临——靶向蛋白降解的第3个十年, objectType=article, longId=222316, objectId=ca74222316a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca74222316a2, replyNumber=0, likeNumber=80, createdTime=2022-08-15, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca74222316a2, moduleTitle=RSC Chem Biol：PROTAC的时代来临——靶向蛋白降解的第3个十年, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca74222316a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033736, encodeId=4e2b2033e3647, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=综述：靶向蛋白降解(PROTACs)癌症治疗药物机制、以及新近进展、国内相关研发公司, objectType=article, longId=209142, objectId=df2420914253, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df2420914253, replyNumber=0, likeNumber=78, createdTime=2021-10-14, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df2420914253, moduleTitle=综述：靶向蛋白降解(PROTACs)癌症治疗药物机制、以及新近进展、国内相关研发公司, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df2420914253)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033734, encodeId=32e92033e3497, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=Eur Radiol：在肝细胞癌TACE术中及术后发生严重腹痛的预测因素, objectType=article, longId=208174, objectId=8b4b2081e4b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b4b2081e4b2, replyNumber=0, likeNumber=87, createdTime=2022-01-27, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b4b2081e4b2, moduleTitle=Eur Radiol：在肝细胞癌TACE术中及术后发生严重腹痛的预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b4b2081e4b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033742, encodeId=ad302033e42fa, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=Neurology：卒中患者合并肾功能不全，强化降压治疗可能适得其反！（ATACH-2研究）, objectType=article, longId=214835, objectId=a62b21483503, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a62b21483503, replyNumber=0, likeNumber=85, createdTime=2021-12-20, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a62b21483503, moduleTitle=Neurology：卒中患者合并肾功能不全，强化降压治疗可能适得其反！（ATACH-2研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a62b21483503)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033740, encodeId=cfb82033e4000, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=Cancers：中性粒细胞/淋巴细胞比（NLR）是中期肝细胞癌（HCC）患者一线接受TACE治疗的预后指标。, objectType=article, longId=212415, objectId=b72721241538, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b72721241538, replyNumber=0, likeNumber=65, createdTime=2021-08-20, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b72721241538, moduleTitle=Cancers：中性粒细胞/淋巴细胞比（NLR）是中期肝细胞癌（HCC）患者一线接受TACE治疗的预后指标。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b72721241538)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033748, encodeId=543b2033e48a4, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效, objectType=article, longId=219974, objectId=ad462199e46a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad462199e46a, replyNumber=0, likeNumber=65, createdTime=2022-04-27, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad462199e46a, moduleTitle=Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad462199e46a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TAC

2020-05-29

grace5700 (审核中...)

前往app查看评论内容

#TAC#

A&R：血浆中的CRTAC1蛋白与骨关节炎相关并预测将来是否需要关节置换：冰岛的大规模蛋白质组学扫描

2022-07-22

grace5700 (审核中...)

前往app查看评论内容

#TAC#

2022年1月10日简报：天津再新增20例奥密克戎感染；塞浦路斯研究人员称发现“德尔塔+奥密克戎”混合毒株Deltacron；南非仅2个月就渡过疫情高峰

2022-11-21

grace5700 (审核中...)

前往app查看评论内容

#TAC#

Front Oncol：TACE联合索拉非尼或阿帕替尼治疗伴有门脉癌栓（PVTT）的肝细胞癌（HCC）患者的疗效

2022-09-20

grace5700 (审核中...)

前往app查看评论内容

#TAC#

Front Immunol：强直性脊柱炎患者外周血单个核细胞的整合单细胞RNA-SEQ和ATAC-SEQ分析

2022-04-02

grace5700 (审核中...)

前往app查看评论内容

#TAC#

Front Oncol：肝切除术(HR)对比TACE治疗中期肝细胞癌(IM-HCC)的疗效

2022-04-12

grace5700 (审核中...)

前往app查看评论内容

#TAC#

J AM COLL RADIOL：肝癌TACE术后该选择何种药物进行疼痛控制？

2023-01-06

grace5700 (审核中...)

前往app查看评论内容

#TAC#

Contact Dermatitis：新冠肺炎大流行期间实习护生手部湿疹的特点

2022-08-23

grace5700 (审核中...)

前往app查看评论内容

#TAC#

治疗C3肾小球肾炎，诺华的 iptacopan 在中期研究中达到临床终点

2022-10-26

grace5700 (审核中...)

前往app查看评论内容

#TAC#

Front Oncol：立体定向放疗（SBRT）联合免疫治疗（SBRT-IO）对比TACE治疗局部进展期肝细胞癌患者的疗效

2021-12-27

grace5700 (审核中...)

前往app查看评论内容

#TAC#

Aspaveli (pegcetacoplan) 治疗阵发性夜间血红蛋白尿症 (PNH)，已获得欧盟CHMP积极意见

2021-11-02

grace5700 (审核中...)

前往app查看评论内容

#TAC#

使用TACE联合放疗治疗原发性肝癌合并门静脉癌栓对患者生存情况的影响分析

2022-03-06

grace5700 (审核中...)

前往app查看评论内容

#TAC#

Hepatology International：仑伐替尼+TACE对比TACE在不可切除肝癌中的疗效：一项回顾性对照研究

2021-07-13

grace5700 (审核中...)

前往app查看评论内容

#TAC#

Liver Cancer：Lenvatinib(仑伐替尼)初始治疗出现应答是仑伐替尼（LEN)+经动脉化疗栓塞(LEN-TACE)序贯治疗的预后指标

2022-03-31

grace5700 (审核中...)

前往app查看评论内容

#TAC#

新药研发利器：PROTAC技术（全面解读）

2022-03-22

grace5700 (审核中...)

前往app查看评论内容

#TAC#

RSC Chem Biol：PROTAC的时代来临——靶向蛋白降解的第3个十年

2022-08-15

grace5700 (审核中...)

前往app查看评论内容

#TAC#

综述：靶向蛋白降解(PROTACs)癌症治疗药物机制、以及新近进展、国内相关研发公司

2021-10-14

grace5700 (审核中...)

前往app查看评论内容

#TAC#

Eur Radiol：在肝细胞癌TACE术中及术后发生严重腹痛的预测因素

2022-01-27

grace5700 (审核中...)

前往app查看评论内容

#TAC#

Neurology：卒中患者合并肾功能不全，强化降压治疗可能适得其反！（ATACH-2研究）

2021-12-20

grace5700 (审核中...)

前往app查看评论内容

#TAC#

Cancers：中性粒细胞/淋巴细胞比（NLR）是中期肝细胞癌（HCC）患者一线接受TACE治疗的预后指标。

2021-08-20

grace5700 (审核中...)

前往app查看评论内容

#TAC#

Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效

2022-04-27

科室
- - 订阅+
  - 更多科室
工具
服务